# Aerie Pharmaceuticals clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Aerie Pharmaceuticals as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Aerie Pharmaceuticals: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/aerie-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 11, 2022 | NCT05497479 | Study Evaluating Techniques for Measuring Tear Production | Aerie Pharmaceuticals | Phase 1 | Completed | Dry Eye Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05497479) |
| August 9, 2022 | NCT05493111 | A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512 | Aerie Pharmaceuticals | Phase 3 | Completed | Dry Eye Disease | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05493111) |
| May 4, 2022 | NCT05360966 | Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3) | Aerie Pharmaceuticals | Phase 3 | Completed | Dry Eye Disease | 467 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05360966) |
| March 17, 2022 | NCT05285644 | Study Evaluating the Safety and Efficacy of AR-15512 | Aerie Pharmaceuticals | Phase 3 | Completed | Dry Eye Disease | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05285644) |
| March 17, 2022 | NCT05283395 | Rocklatan® Evaluation | Aerie Pharmaceuticals | Phase 4 | Completed | Glaucoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05283395) |
| November 6, 2020 | NCT04620135 | Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in... | Aerie Pharmaceuticals | Phase 3 | Completed | Primary Open Angle Glaucoma, Ocular Hypertension | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04620135) |
| August 4, 2020 | NCT04498182 | A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease | Aerie Pharmaceuticals | Phase 2 | Completed | Dry Eye Disease | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04498182) |
| August 4, 2020 | NCT04498169 | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal... | Aerie Pharmaceuticals | Phase 2 | Completed | Corneal Edema | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04498169) |
| February 19, 2019 | NCT03844945 | Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular... | Aerie Pharmaceuticals | Phase 2 | Completed | Open Angle Glaucoma, Ocular Hypertension | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03844945) |
| February 11, 2019 | NCT03835884 | A Study Assessing AR-13503 Implant in Subjects With nAMD or DME | Aerie Pharmaceuticals | Phase 1 | Completed | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03835884) |
| January 17, 2019 | NCT03808688 | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world... | Aerie Pharmaceuticals | Phase 4 | Completed | Glaucoma, Open-Angle, Ocular Hypertension | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03808688) |
| November 14, 2018 | NCT03739593 | Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) | Aerie Pharmaceuticals | Phase 2 | Completed | Macular Edema | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03739593) |
| October 16, 2017 | NCT03310580 | Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 2 | Completed | Primary Open Angle Glaucoma or Ocular Hypertension | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03310580) |
| September 15, 2017 | NCT03284853 | Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in... | Aerie Pharmaceuticals | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03284853) |
| July 28, 2017 | NCT03233308 | Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) | Aerie Pharmaceuticals | Phase 2 | Completed | Primary Open Angle Glaucoma or Ocular Hypertension | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03233308) |
| August 22, 2016 | NCT02874846 | Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution | Aerie Pharmaceuticals | Phase 2 | Completed | Ocular Hypertension, Open Angle Glaucoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02874846) |
| February 5, 2016 | NCT02674854 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Open-angle Glaucoma, Ocular Hypertension | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02674854) |
| September 24, 2015 | NCT02558400 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Open-angle Glaucoma, Ocular Hypertension | 718 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02558400) |
| September 24, 2015 | NCT02558374 | Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Open-angle Glaucoma, Ocular Hypertension | 708 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02558374) |
| April 2, 2015 | NCT02406287 | A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers | Aerie Pharmaceuticals | Phase 1 | Completed | Healthy Subjects | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02406287) |
| September 23, 2014 | NCT02246764 | Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Ocular Hypertension, Glaucoma | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02246764) |
| August 4, 2014 | NCT02207621 | Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Ocular Hypertension, Open-angle Glaucoma | 756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02207621) |
| August 4, 2014 | NCT02207491 | Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Aerie Pharmaceuticals | Phase 3 | Completed | Ocular Hypertension, Open-angle Glaucoma | 411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02207491) |
| February 7, 2014 | NCT02057575 | Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure | Aerie Pharmaceuticals | Phase 2 | Completed | Open Angle Glaucoma, Ocular Hypertension | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02057575) |
| November 28, 2013 | NCT01997879 | Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers | Aerie Pharmaceuticals | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01997879) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 18 |
| Phase 3 | 11 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ocular Hypertension | 22 |
| Glaucoma, Open-Angle | 18 |
| Glaucoma | 13 |
| Dry Eye Syndromes | 5 |
| Corneal Edema | 1 |
| Fuchs' Endothelial Dystrophy | 1 |
| Diabetic Retinopathy | 1 |
| Macular Edema | 1 |
| Retinal Vein Occlusion | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
- [Prosthodontics practices in the United States](https://specstream.ai/data/businesses/prosthodontics-practices/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
